newsfilter
← Latest News
GlobeNewswire·

Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs

Company continues to expand and accelerate its R&D strategies for high-impact translational and clinical programs in the US and Europe Intended SenlangBio acquisition terminated, eliminating potential 80 million share issuance FREEHOLD, N.J., Jan.